The key role for activation of this pathway in fibrosis was borne out in clinical trials where drugs such as GLPG1690 (an ATX inhibitor) and BMS986020 (an LPA1 receptor antagonist) attenuated the progression of IPF [25,26]. This evidence concerns the gene ENPP2 and idiopathic pulmonary fibrosis.